Expanded New Born Bloodspot Screening: Developed Country Examples And Shat Can Be Done In Turkey

dc.contributor.authorFidan, Caglar
dc.contributor.authorOrun, Huseyin
dc.contributor.authorAlper, Asli Begum
dc.contributor.authorUnver, Cigdem Naz
dc.contributor.authorSahin, Omer Can
dc.contributor.authorUgurlu, Zeynep
dc.contributor.authorAkdur, Recep
dc.contributor.authorTaruscio, Domenica
dc.contributor.orcIDhttps://orcid.org/0000-0002-4384-0881en_US
dc.contributor.orcIDhttps://orcid.org/0000-0002-1713-4342en_US
dc.contributor.pubmedID35702584en_US
dc.contributor.researcherIDAAG-9736-2019en_US
dc.contributor.researcherIDGPW-7632-2022en_US
dc.date.accessioned2022-12-14T10:44:33Z
dc.date.available2022-12-14T10:44:33Z
dc.date.issued2022
dc.description.abstractBloodspot screening in newborns is an exemplary public health intervention as it is essential secondary prevention with proven efficacy and benefit for the early diagnosis and prompt treatment of rare diseases. In this mini review, newborn bloodspot screening (NBS) programs of 12 countries were examined in terms of the extent of diseases/disorders screened to form recommendations for Turkey's expanded newborn screening program. Essentially, Turkey and 11 selected countries' official policies/ national programs or strategies in terms of newborn screening and the number of diseases/conditions screened were examined. The current status of spinal muscular atrophy (SMA) screening was also checked through the SMA NBS Alliance. In addition, WHO and EURORDIS guidelines for newborn screening were also reviewed. On the Pubmed database, following the search strategy "((newborn screening[Title/Abstract]) OR (newborn screening program[Title/Abstract])) OR (newborn blood spot screening[Title/Abstract])" in the PubMed database from 1 January 2008 to 1 December 2021. Diseases that will be recommended to be included in the Turkish national newborn bloodspot screening program will be presented by evaluating the updated criteria of Wilson and Jungner by constructing international comparisons. The number of diseases/disordeis screened by the inspected 12 countries is eminently variable and ranges from 5 in Turkey to 51 in New York, United States of America (USA). Acknowledging the programs of other countries, it is evident that Turkey must advance its program by evaluating the epidemiological data in Turkey, the health workforce, and infrastructure while relying on the updated screening criteria. The newborn bloodspot screening program should be expanded based on the cost estimates and implemented starting with pilot applications and the diseases/disorders that are deemed appropriate should be included in the national program.en_US
dc.identifier.endpage69en_US
dc.identifier.issn2186-3644en_US
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85133839662en_US
dc.identifier.startpage63en_US
dc.identifier.urihttps://www.jstage.jst.go.jp/article/irdr/11/2/11_2022.01039/_pdf/-char/en
dc.identifier.urihttp://hdl.handle.net/11727/8294
dc.identifier.volume11en_US
dc.identifier.wos000806786800003en_US
dc.language.isoengen_US
dc.relation.isversionof10.5582/irdr.2022.01039en_US
dc.relation.journalINTRACTABLE & RARE DISEASES RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectrare diseasesen_US
dc.subjectneonatal screeningen_US
dc.subjectnewborn screeningen_US
dc.subjectdried blood spotsen_US
dc.subjectsecondary preventionen_US
dc.titleExpanded New Born Bloodspot Screening: Developed Country Examples And Shat Can Be Done In Turkeyen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
95.pdf
Size:
319.13 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: